Transcatheter arterial chemoembolisation for hepatocellular carcinoma in cirrhosis: survival rate and prognostic factors

Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Mirko OlivoMario Cottone

Abstract

The role of prognostic variables in the treatment of hepatocellular carcinoma (HCC) by transarterial chemoembolisation (TACE) is controversial. To evaluate the survival of patients with HCC on cirrhosis treated with TACE and to analyse the prognostic factors affecting survival. From 1996 to 2006, 580 consecutive patients with HCC in cirrhosis were observed. Of these 194 patients underwent TACE. The primary end-point was survival. Independent predictors of survival were identified using the Cox model. The cumulative 1-year, 3-year, and 5-year survival rates were 96%, 60%, and 41%, respectively. The multivariate analysis showed significant reduction of survival among patients with serum bilirubin values >2mg/dl compared to patients with values <2mg/dl (Hazard ratio 3.84; CI 95% 1.70-8.66; p-value=0.001). Multivariate analysis performed in the group of patients treated with TACE alone showed that elevated serum bilirubin (Hazard ratio 2.96; CI 95% 1.20-7.3; p-value 0.02) and incomplete tumour response (Hazard ratio 2.88; CI 95% 1.18-7.05; p-value 0.02) are correlated with a worse outcome. TACE was well tolerated and overall survival rate was 41% after 5 years. Complete tumour response and serum bilirubin <2mg/dl were identified as...Continue Reading

References

Nov 1, 1987·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·E Christensen
Oct 23, 2001·International Journal of Cancer. Journal International Du Cancer·D M ParkinP Pisani
May 1, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Chung-Mau LoJohn Wong
Jan 24, 2003·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Josep M Llovet, Jordi Bruix
Nov 27, 2004·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Margarita SalaUNKNOWN Barcelona Clínic Liver Cancer Group
Oct 20, 2005·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Maurizio BiselliMauro Bernardi
Oct 27, 2005·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jordi BruixUNKNOWN Practice Guidelines Committee, American Association for the Study of Liver Diseases
Jan 4, 2006·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·J DumortierP-J Valette
Aug 8, 2006·Gastroenterology·Kenichi TakayasuUNKNOWN Liver Cancer Study Group of Japan
Apr 17, 2009·World Journal of Gastroenterology : WJG·Rodolfo SaccoAlfonso Capria

❮ Previous
Next ❯

Citations

Jan 8, 2013·Medical Oncology·Ji-Wen Cheng, Yi Lv
May 16, 2013·World Journal of Gastroenterology : WJG·Matan J CohenOren Shibolet
Jun 27, 2013·World Journal of Gastroenterology : WJG·Ke-Tong WuChuan-Xing Li
Feb 5, 2013·HPB : the Official Journal of the International Hepato Pancreato Biliary Association·Jon C HenryCarl R Schmidt
Feb 2, 2013·Journal of Vascular and Interventional Radiology : JVIR·Sanjeeva P KalvaAndrew X Zhu
May 14, 2011·Alimentary Pharmacology & Therapeutics·G CabibboC Cammà
Apr 24, 2013·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Yoshifumi SaitoKoichi Tokuuye
Feb 12, 2014·Liver International : Official Journal of the International Association for the Study of the Liver·Matan J CohenOren Shibolet

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.